🎧 Listen to this article

Your doctor measured your weight. Your A1C. Maybe your blood pressure. All improving. But there’s one thing nobody’s checking while you’re on Ozempic or Wegovy — and it’s the thing that matters most ten years from now.

Your bones.

We already covered how GLP-1 drugs strip away muscle and bone together. This time, we’re going deeper into what happens to your skeleton specifically — because the fracture risk data is starting to come in, and it’s not what the cheerfully optimistic headlines suggest.

What’s actually happening to your bones on GLP-1 drugs

Bone isn’t the static, chalk-like material most people imagine. It’s living tissue. Your body constantly breaks down old bone (resorption) and builds new bone (formation) in a tightly coupled cycle called remodeling. When that cycle gets disrupted — faster breakdown, slower building — you lose density. Over time, that means fractures.

GLP-1 receptor agonists interfere with this cycle in at least three ways:

1. Rapid weight loss itself causes bone loss.

This isn’t unique to GLP-1 drugs. Any significant weight loss — bariatric surgery, crash dieting, illness — reduces mechanical load on your skeleton. Your bones respond to the forces placed on them (Wolff’s Law). Less body weight means less stimulus to maintain density. A 2024 narrative review in Calcified Tissue International confirmed that bone loss during GLP-1 treatment is at least partly driven by the weight loss itself, not just the drug. (Herrou et al., 2024)

2. GLP-1 receptors exist on bone cells.

This is the part that should make you pay attention. GLP-1 receptors aren’t just in your gut and pancreas. They’ve been identified on osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells). The drug isn’t just causing weight loss that indirectly affects bones — it’s potentially acting on bone tissue directly. Research is still sorting out whether the net effect is protective or harmful, but a 2025 critical appraisal in Diabetes, Obesity and Metabolism concluded that the evidence leans toward a neutral-to-negative effect on bone density with most GLP-1 agonists. (Anastasilakis et al., 2025)

3. Caloric deficit impairs mineral absorption.

When you’re eating significantly less — which is the whole point of GLP-1 drugs — you’re also absorbing less calcium, magnesium, and vitamin D. These are the raw materials your bones need to rebuild. A 2025 review in International Journal of Obesity noted that older adults on GLP-1 drugs are particularly vulnerable because they already have reduced absorption efficiency and lower baseline reserves. (Henney et al., 2025)

The fracture data — what we know so far

Here’s where it gets real.

A June 2026 study in The Journal of Clinical Endocrinology & Metabolism specifically looked at semaglutide and tirzepatide in patients already at increased fracture risk. The findings suggest that while these drugs help with metabolic markers, they don’t protect bone — and in some cases, bone loss accelerated during treatment. (Liu et al., 2026)

Another June 2026 study from the same journal looked at fragility fractures in older adults with type 2 diabetes on GLP-1 receptor agonists. The results were concerning enough that the authors called for routine bone density monitoring in patients on these drugs. (Kasher Meron et al., 2026)

And a real-world 2025 study published in Frontiers in Endocrinology found that GLP-1 receptor agonist use was associated with increased osteoporosis risk among type 2 diabetes patients — not decreased, as some had hoped. (Chen et al., 2025)

Even the comparison data is sobering. A 2025 retrospective cohort study using the TriNetX database found that tirzepatide users had comparable osteoporosis risk to users of other GLP-1 agonists — meaning the newer, more potent drugs aren’t necessarily better for your skeleton. (Hsu et al., 2025)

Why this is happening to you specifically

If you’re a woman over 35, you’re already on the losing side of the bone density curve. Peak bone mass hits around 30. After that, you’re slowly declining — and perimenopause accelerates the drop dramatically as estrogen falls.

Now layer on a GLP-1 drug. You’re losing weight (reduced mechanical loading). You’re eating less (reduced mineral intake). You may be absorbing less calcium and vitamin D. And the drug itself may be acting on your bone cells.

It’s not one thing. It’s all of them at once.

Your doctor is monitoring your weight, your blood sugar, maybe your lipids. But is anyone checking your DEXA scan? Your vitamin D levels? Your calcium intake? Almost certainly not.

What you can do today

1. Get a baseline DEXA scan.

If you’re on a GLP-1 drug and plan to be for more than six months, ask for a dual-energy X-ray absorptiometry scan. This measures your bone mineral density at the hip and spine. You need a baseline to compare against — otherwise you won’t know what you’ve lost until something breaks.

2. Supplement calcium and vitamin D3 + K2.

You’re eating less. Your bones still need the same minerals. Aim for 1,000–1,200 mg of calcium daily from food and supplements combined. Vitamin D3 (2,000–5,000 IU daily) helps you absorb calcium; vitamin K2 (100–200 mcg) directs it into bone instead of arteries. This combination works synergistically — D3 without K2 can actually calcify your blood vessels.

3. Prioritize protein — including collagen.

Bone matrix is roughly 90% collagen. If you’re in a caloric deficit, your body cannibalizes its own collagen stores. Supplementing with collagen peptides gives your osteoblasts the raw materials they need. Research on specific collagen peptides for bone is still emerging, but the mechanism is sound.

4. Lift heavy things.

Resistance training is the single most effective non-pharmaceutical intervention for bone density. Your bones respond to mechanical stress by building more tissue. This is especially critical if you’re on a GLP-1 drug because you need to replace the mechanical load that weight loss removes. Two to three sessions per week focusing on compound movements (squats, deadlifts, presses) is the minimum.

5. Monitor, don’t guess.

Ask your doctor to check your 25-hydroxyvitamin D level, your calcium, and your bone-specific markers (CTX for resorption, P1NP for formation). These give you a real-time picture of what’s happening in your bones, not just a snapshot every two years.

What to stop doing

Stop assuming your doctor is monitoring this. They’re not. GLP-1 prescribing guidelines focus on metabolic outcomes. Bone health is an afterthought. You need to advocate for yourself.

Stop skipping meals. The appetite suppression from GLP-1 drugs makes it easy to eat almost nothing. But every skipped meal is a missed opportunity to deliver calcium, protein, and minerals to your skeleton. Even a small, nutrient-dense meal is better than nothing.

Stop relying on calcium from food alone. If you’re eating 800 calories a day on semaglutide, you’re probably getting 300–400 mg of calcium. That’s less than half of what your bones need. Supplementation isn’t optional during GLP-1 treatment.

The supplement question

If you’re going to add one supplement to your GLP-1 protocol, make it a calcium + D3 + K2 combo. Your bones need all three working together — calcium as the raw material, D3 to absorb it, and K2 to direct it to the right places.

SOLARAY Vitamin D3 K2 — Combines D3 with K2 for calcium absorption and bone strength. A solid daily foundation if you’re on GLP-1 drugs and eating less.

NOW Foods Collagen Peptides Powder — Clinically tested collagen for joint and bone support. Mixes into coffee or smoothies — useful when your appetite is suppressed and you need concentrated nutrition.

Nutricost Creatine Monohydrate — Creatine supports muscle retention during weight loss, and emerging research suggests it may benefit bone density too, especially when combined with resistance training.

If you want the full breakdown on why creatine matters for women over 35 — including the bone angle — read this.

Disclosure: This post contains affiliate links. If you purchase through these links, I may earn a small commission at no cost to you.

What we still don’t know

The honest answer: we don’t have long-term fracture outcome data for GLP-1 drugs specifically. The studies showing increased osteoporosis risk are mostly observational and retrospective. The randomized controlled trials that got these drugs approved didn’t include DEXA scans as a primary endpoint — which means the companies selling these drugs never had to prove they were safe for your bones.

That’s not an accident. It’s a gap. And it’s one you need to fill yourself, because no one is coming to fill it for you.

The bone you lose on GLP-1 drugs today might not show up as a fracture for ten or fifteen years. By then, the conversation will have moved on. Protect yourself now.

Save this for someone who needs to hear it before their next Ozempic refill.